{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:36:10Z","timestamp":1767144970868,"version":"build-2238731810"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2320-B-038-056"],"award-info":[{"award-number":["MOST 111-2320-B-038-056"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bbrc.2023.09.025","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:39:15Z","timestamp":1694738355000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer"],"prefix":"10.1016","volume":"680","author":[{"given":"Chen-Wei","family":"Chiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Shih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-5820","authenticated-orcid":false,"given":"Fu-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keng-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-9029","authenticated-orcid":false,"given":"Yu-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.09.025_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2023.09.025_bib2","doi-asserted-by":"crossref","first-page":"13718","DOI":"10.3748\/wjg.v20.i38.13718","article-title":"Adjuvant therapy for gastric cancer: current and future directions","volume":"20","author":"Foo","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib3","doi-asserted-by":"crossref","first-page":"12892","DOI":"10.3748\/wjg.v20.i36.12892","article-title":"Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects","volume":"20","author":"Merrett","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejso.2015.10.016","article-title":"Surgical management of advanced gastric cancer: an evolving issue","volume":"42","author":"Marano","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2023.09.025_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.20517\/2394-4722.2017.76","article-title":"Current trends in gastric cancer treatment in Europe","volume":"4","author":"Kamiya","year":"2018","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.bbrc.2023.09.025_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrm856","article-title":"Mechanisms and functions of Eph and ephrin signalling","volume":"3","author":"Kullander","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.devcel.2004.09.006","article-title":"Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly","volume":"7","author":"Poliakov","year":"2004","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrc.2023.09.025_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/0008-5472.CAN-20-3047","article-title":"Eph receptors in the immunosuppressive tumor microenvironment","volume":"81","author":"Janes","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.025_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.09.025_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6890-13-19","article-title":"EphA4 is a prognostic factor in gastric cancer","volume":"13","author":"Miyazaki","year":"2013","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib13","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3748\/wjg.14.5650","article-title":"Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers","volume":"14","author":"Oki","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib14","first-page":"1685","article-title":"Prognostic significance of high EphA1-4 expression levels in locally advanced gastric cancer","volume":"38","author":"Inokuchi","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2023.09.025_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11010-017-3139-1","article-title":"MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4","volume":"439","author":"Dong","year":"2018","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2023.09.025_bib16","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1535-7163.MCT-07-2263","article-title":"EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line","volume":"7","author":"Fukai","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2023.09.025_bib17","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41388-020-1178-7","article-title":"C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer","volume":"39","author":"Lee","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.025_bib18","article-title":"Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1(G93A) ALS mouse model","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2023.09.025_bib19","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/nm.2901","article-title":"EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans","volume":"18","author":"Van Hoecke","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2023.09.025_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-1759(00)00221-0","article-title":"Methods for the generation of chicken monoclonal antibody fragments by phage display","volume":"242","author":"Andris-Widhopf","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bbrc.2023.09.025_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/prot.10389","article-title":"ZDOCK: an initial-stage protein-docking algorithm","volume":"52","author":"Chen","year":"2003","journal-title":"Proteins"},{"key":"10.1016\/j.bbrc.2023.09.025_bib22","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2023.09.025_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib24","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib25","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2023.09.025_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","article-title":"Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial","volume":"25","author":"Fuchs","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bbrc.2023.09.025_bib27","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbrc.2023.09.025_bib28","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of Nivolumab and Nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.bbrc.2023.10.017","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000}}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23010616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23010616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:48:41Z","timestamp":1762094921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23010616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"alternative-id":["S0006291X23010616"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.09.025","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}